• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

NICHD RTC Secondary Analysis: What is the Impact of Indicated vs Spontaneous Preterm Birth on Pregnancy Outcomes?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Up to 75% of preterm birth is spontaneous (SPTB) while remainder are indicated (IPTB) deliveries, based on maternal or fetal complications
  • Public health policy may suggest focusing resources on the more common SPTB cohort, but there is limited data as to which group has the burden of adverse events
  • Tita et al. (American Journal of Perinatology, 2018) compared the risks of adverse maternal and neonatal outcomes associated SPTB vs IPTB

METHODS:

  • Retrospective Cohort Study
    • Secondary analysis of multicenter trial including women with SPTB and IPTB
    • Original study: NICHD RCT of vitamin C and E to prevent preeclampsia in low risk nulliparous patients
  • Primary exposure: PTB (<37w0d) – SPTB vs IPTB
  • Primary maternal outcome: Composite of the following
    • Death |Pulmonary edema |Blood transfusion | ARDS | Cerebrovascular accident | ATN | DIC | Liver rupture
  • Primary neonatal outcome: Composite of the following
    • Neonatal death | RDS | Grades III or IV IVH |Sepsis | NEC | ROP

RESULTS:

  • 9,867 women were included in the study
    • 1,038 women underwent preterm births
    • 340 IPTBs
    • 698 SPTBs

Maternal Adverse Events

  • Composite maternal outcome was more frequent in IPTB (4.4%) vs SPTB (0.9%)
    • adjusted odds ratio [aOR], 4.0 (95% CI, 1.4–11.8)
  • Blood transfusion was more common in IPTB (3.4%) vs SPTB (0.9%); P=0.005
    • aOR 3.2 (95% CI, 1.1-9.8)
  • Prolonged hospital stay was more frequent in ITPB (8.7%) vs SPTB (1.8%); P<0.001
    • aOR 3.7 (95% CI, 1.8-7.7)

Newborn Adverse Events

  • Composite neonatal outcome was less frequent in IPTB (22.6%) vs SPTB (24.1%) but when adjusted for confounders inlcuding demographics and peripartum infections, risk increased
    • aOR, 1.8 (95% CI, 1.1–3.0)
  • Other outcomes that were increased in IPTB vs STB group
    • RDS: aOR 1.7 (95% CI, 1.1-2.7)
    • SGA <5th percentile: aOR 7.9 (95% CI, 4.0-15.7)
    • NICU admission: aOR 1.8 (95% CI, 1.3-2.5)
  • Crude risk of death higher in SPTB
  • Most frequent reason for IPTB was pregnancy-associated hypertension
    • Outcomes for this indication only were similar to the overall group, except that neonatal composite and RDS were no longer statistically different

CONCLUSION:

  • IPTB vs SPTB have a fourfold higher incidence of maternal adverse events
  • The authors state that based on the results of this study “interventions to prevent the underlying causes of IPTBs such as preeclampsia, to reduce the risk of IPTBs and hence reduce the associated burden of adverse outcomes may deserve as much attention as directed toward SPTBs”

Learn More – Primary Sources:

Adverse Maternal and Neonatal Outcomes in Indicated Compared with Spontaneous Preterm Birth in Healthy Nulliparas: A Secondary Analysis of a Randomized Trial

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Antenatal Corticosteroids – When to Administer?
Are Vitamin D Levels Linked to Preeclampsia and Preterm Birth?
Progesterone or Cerclage in Preterm Prevention in Women with Previous Preterm Birth and Short Cervix?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site